Status:
RECRUITING
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Migraine
Episodic Migraine
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor:...
Detailed Description
It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies...
Eligibility Criteria
Inclusion
- Migraine diagnosis according to ICHD-III.
- Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
- Signature of informed consent.
Exclusion
- Presence of headache different from migraine.
- Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Key Trial Info
Start Date :
January 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT07159750
Start Date
January 2 2024
End Date
January 1 2026
Last Update
September 8 2025
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami, Miller School of Medicine
Miami, Florida, United States, 33136
2
FLENI
Buenos Aires, Argentina
3
Pontificia Universidad Católica de Chile
Santiago, Chile
4
Neuromedica
Medellín, Colombia